Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Lambertini

Showing results (331-340 of 375) with videos related to

Pageof 38
Sort By:
The Lancet. Oncology|November 12, 2022
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trialLucia Del Mastro, Francesca Poggio, Eva Blondeaux, et al.
Cancer Treatment Reviews|October 6, 2022
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancerFrancesco Schettini, Sergio Venturini, Mario Giuliano, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysisGiuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2023
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast CancerMatteo Lambertini, Marcello Ceppi, Richard A Anderson, et al.
The Lancet. Oncology|December 15, 2024
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trialIcro Meattini, Maria Carmen De Santis, Luca Visani, et al.
Eclinicalmedicine|May 31, 2023
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studiesMatteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, et al.
NPJ Breast Cancer|March 5, 2026
RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancerAlba Llop-Guevara, Benedetta Pellegrino, Isabel Pimentel, et al.
Cancers|September 10, 2021
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast CancerFrancesco Schettini, Mario Giuliano, Matteo Lambertini, et al.
Histopathology|April 21, 2026
World Health Organization classification of tumours of the breast 6th edition 2026Cecily Quinn, Puay Hoon Tan, Kimberly H Allison, et al.
Journal of the National Cancer Institute|December 7, 2023
Taxanes for the treatment of breast cancer during pregnancy: an international cohort studyAna S Ferrigno Guajardo, Bryan F Vaca-Cartagena, Erica L Mayer, et al.
Pageof 38

Showing results (331-340 of 375) with videos related to

Sort By:
Pageof 38
The Lancet. Oncology|November 12, 2022
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trialLucia Del Mastro, Francesca Poggio, Eva Blondeaux, et al.
Cancer Treatment Reviews|October 6, 2022
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancerFrancesco Schettini, Sergio Venturini, Mario Giuliano, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysisGiuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2023
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast CancerMatteo Lambertini, Marcello Ceppi, Richard A Anderson, et al.
The Lancet. Oncology|December 15, 2024
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trialIcro Meattini, Maria Carmen De Santis, Luca Visani, et al.
Eclinicalmedicine|May 31, 2023
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studiesMatteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, et al.
NPJ Breast Cancer|March 5, 2026
RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancerAlba Llop-Guevara, Benedetta Pellegrino, Isabel Pimentel, et al.
Cancers|September 10, 2021
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast CancerFrancesco Schettini, Mario Giuliano, Matteo Lambertini, et al.
Histopathology|April 21, 2026
World Health Organization classification of tumours of the breast 6th edition 2026Cecily Quinn, Puay Hoon Tan, Kimberly H Allison, et al.
Journal of the National Cancer Institute|December 7, 2023
Taxanes for the treatment of breast cancer during pregnancy: an international cohort studyAna S Ferrigno Guajardo, Bryan F Vaca-Cartagena, Erica L Mayer, et al.
Pageof 38